Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04777084
Status:
RECRUITING
Last Update Posted:
2023-12-27
First Post:
2021-02-27
Brief Title:
The Efficacy and Safety of the Bispecific Anti-PD-1PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC
Sponsor:
Organization:
Hunan Province Tumor Hospital